Amgen Inc (AMGN) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $385.65 (+1.55%), Market cap $179.05B, P/E ratio 23.09, 52-week low–high $271.18 ~ $388.16.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma;
Financial statements, price targets, institutional (13F) holdings and related news for Amgen Inc are updated in real time on BlackAll Trade.
7 recent posts · 7 bullish · 0 bearish · 0 neutral.
Amgen Inc trades at $385.65 (+1.55%). Real-time quotes and charts are available on BlackAll Trade.
Amgen Inc has a market cap of about $179.05B. Its P/E ratio is 23.09.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, an